trending Market Intelligence /marketintelligence/en/news-insights/trending/bsJAE8HcksN-Te5uENyitQ2 content esgSubNav
In This List

Pharmarise fiscal Q2 profit climbs 8.1% YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Pharmarise fiscal Q2 profit climbs 8.1% YOY

Pharmarise Holdings Corp. said its normalized net income for the fiscal second quarter ended Nov. 30, 2014, amounted to ¥20.31 per share, a decrease of 11.2% from ¥22.86 per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥186.5 million, a gain of 8.1% from ¥172.5 million in the year-earlier period.

The normalized profit margin increased to 1.9% from 1.9% in the year-earlier period.

Total revenue increased 6.6% on an annual basis to ¥9.87 billion from ¥9.25 billion, and total operating expenses grew 6.6% on an annual basis to ¥9.49 billion from ¥8.90 billion.

Reported net income grew year over year to ¥107.9 million, or ¥11.75 per share, from ¥52.7 million, or ¥6.93 per share.

As of Jan. 14, US$1 was equivalent to ¥116.84.